<DOC>
	<DOCNO>NCT01252875</DOCNO>
	<brief_summary>The aim study evaluation two usual care strategy stroke TIA : achieve target LDL-C 100 mg/dL ( +/-10 mg/dL ) less 70 mg/dL . Investigators use statin titrate dosage achieve target assign randomization monotherapy combination ezetimibe drug . The primary end-point occurrence recurrent non fatal stroke , non fatal MI , vascular death group . 3760 patient recruit follow eight half year maximum .</brief_summary>
	<brief_title>Treat Stroke Target</brief_title>
	<detailed_description>The aim study evaluation two usual care strategy stroke TIA : achieve target LDL-C 100 mg/dL ( +/-10 mg/dL ) less 70 mg/dL . Investigators use statin titrate dosage achieve target assign randomization monotherapy combination ezetimibe drug . Inclusion criterion : - Recent ( le 3 month ) ischemic stroke As soon possible event , neurologic deficit stabilize ( investigator judgment ) . These ischemic stroke include TIA ischemic lesion document CT MRI . - Or recent TIA ( less 15 day ) without documentation ischemic lesion CT/MR imaging . Must limb weakness aphasia last 10 min . - And document atherosclerotic stenosis carotid artery ( investigator judgment ) ( base result Duplex echography , CTA , MRA X ray- angiography ) , Or aortic arch ( investigator judgment ) ( base TEE CTA ) , Or brain artery : vertebral , basilar intracranial artery ( base CTA , MRA , XRA ) , Or coronary artery ( past history acute coronary syndrome , coronary revascularization positive coronary angiography ) - And statin treatment indicated , follow ANSM guideline ( French drug agency ) , age &gt; 18 year , rankin score ≤ 4 , patient legal representative sign consent , patient affiliate social security system Exclusion criterion : - Ischemic stroke/TIA du arterial dissection ( investigator judgment ) - Cardiac source embolism ( e.g. , mitral stenosis , endomyocardial fibrosis ) without document atherosclerotic stenosis : patient atrial fibrillation past history recent myocardial infarction calcify aortic stenosis randomize otherwise fulfils inclusion criterion - Symptomatic hemorrhagic stroke : Presence microbleeds gradient echo imaging ( T2* ) exclusion criterion . Hemorrhagic transformation ischemic stroke exclusion criterion - Uncontrolled hypertension ( investigator judgment ) - LDL-C &lt; 100 mg/dL patient treatment intensification impossible - F/U impossible bad observance anticipate . - Co-morbid condition may interfere F/U evaluation primary endpoint - Participation another clinical trial The primary end-point : occurrence recurrent non fatal stroke , non fatal MI , vascular death group . Secondary endpoint : - Fatal non fatal stroke - Stroke TIA - Major coronary event ( MI , sudden death , coronary revascularization ACS ) - Any coronary endpoint ( MI , hospitalization ACS , coronary revascularization ) - Any revascularization procedure ( coronary , carotid , peripheral ) - Carotid revascularization ( either surgical endovascular ) - Vascular death - Total death Hypothesis : - Follow-up three year - Risk primary end-point control group ( Target LDL &lt; 100 mg/dL ) : 4 % per year ( 12 % 36 month ) - 5 % Alpha , 80 % power , total number subject : - 3068 patient RRR 25 % - 20 % drop-out : 3760 patient ( 385 primary EP ) Study specification Follow-up : eight half year Follow-up visit : every 6 month Number center ( French Stroke Units , auspice French Neurovascular Society ) : 60-100 Ancillary study As ancillary study , 800 patient ( 400 arm 4 center ) participate TST-PLUS ( Plaque Ultrasound Study ) , three ultrasound examination ( baseline , 1 year 3 year ) baseline blood sampling . The primary endpoint substudy rate occurrence new carotid plaque , hypothesis Rate plaque occurrence &lt; 100 mg/dL group 25 % 3 year ( 45 % EVA atherosclerosis present baseline ) RRR plaque 25 % &lt; 70 mg/dL group Alpha 5 % , power 80 % As ancillary study , 1000 patient participate TST-PGS ( Pharmacogenetics ) Study , 1 blood sample either baseline one follow-up visit TST . The aim study show benefit ( risk ischemic stroke , myocardial infarction , vascular death ) observe strategy LDL-C &lt; 0.7 g / l compare strategy LDL-C 1 ± 0.1 g / l high carrier polymorphism 719Arg gene KIF-6 non-carriers polymorphism .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>• Recent ( less 3 month ) ischemic stroke As soon possible event , neurologic deficit stabilize ( investigator judgment ) These ischemic stroke include TIA ischemic lesion document CT MRI • Or recent TIA ( less 15 day ) without documentation ischemic lesion CT/MR imaging Must limb weakness aphasia last 10 min • And document atherosclerotic stenosis In carotid artery ( investigator judgment ) ( base result Duplex echography , CTA , MRA X ray angiography ) Or aortic arch ( investigator judgment ) ( base TEE CTA ) Or brain artery : vertebral , basilar intracranial artery ( base CTA , MRA , XRA ) Or coronary artery ( past history acute coronary syndrome , coronary revascularization positive coronary angiography ) • And Statin treatment indicate , follow ANSM guideline ( French drug agency ) age &gt; 18 year rankin score ≤ 4 patient legal representative sign consent Patient affiliate social security system • Ischemic stroke/TIA du arterial dissection ( investigator judgment ) Cardiac source embolism ( e.g. , mitral stenosis , endomyocardial fibrosis ) without document atherosclerotic stenosis : patient atrial fibrillation past history recent myocardial infarction calcify aortic stenosis randomize otherwise fulfils inclusion criterion • Symptomatic hemorrhagic stroke Presence microbleeds gradient echo imaging ( T2* ) exclusion criterion . Hemorrhagic transformation ischemic stroke exclusion criterion Uncontrolled hypertension ( investigator judgment ) LDLC &lt; 100 mg/dL patient treatment intensification impossible F/U impossible bad observance anticipate . Comorbid condition may interfere F/U evaluation primary endpoint Participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LDL-C</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Stroke</keyword>
	<keyword>Transient ischemic attack</keyword>
	<keyword>Statin</keyword>
	<keyword>Lipid lower therapy</keyword>
</DOC>